Age-Related Macular Degeneration (AMD) Market Analysis by Top Companies, Trends and Future Prospects Details for Business Development


Posted November 21, 2019 by PramodKumr24

Registering a CAGR of 7.6% during the forecast period (2016–2022), the global age-related macular degeneration (AMD) market is projected to garner $8.9 billion by 2022, significantly growing from $5.3 billion in 2015.
 
The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.

Explore Report with Detailed TOC at:
https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market

Based on type, the AMD market is bifurcated into wet AMD and dry AMD. Between the two, during the historical period (2012–2015), the larger revenue in the market was generated by the wet AMD type. This type of AMD is caused due to the abnormal growth of blood vessels from the choroid layer, which is situated beneath the macula. It is also known as neovascular macular degeneration, and even though it accounts for only 10–15% of AMD cases, it is expected to be the faster growing category in the forecast period.

Download Report Sample at:
https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market/report-sample

The AMD market is witnessing the trend of the rising awareness about the disease. Various activities, campaigns, and programs are being conducted by NGOs, healthcare providers, and optometrists’ associations to sensitize people about the disease and its course of treatment. February is celebrated as the National AMD awareness month as a measure to encourage people to educate themselves about the disease and understand the risk factors and be aware in case they exhibit any of the symptoms. The awareness about the disease has also resulted in increased funding for research related to the AMD.

With the rising awareness about the disease, more funding is being allocated in the research and development of AMD therapeutics. This is resulting in the increase in the number of AMD pipeline drugs. Currently, the U.S. Food and Drug Administration has not approved any drug in the age-related macular degeneration (AMD) market for dry AMD. Therefore, the need to investigate more compounds with possible therapeutics properties is rising. Some of the major investigational compounds in the market are Roche/Genentech’s lampalizumab, MacuCLEAR’s MC1101, and Allergan’s brimonide implant.

Therefore, the market for AMD is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Pramod Kumar
Phone 03479606455
Business Address Block-13, Sector 2, Noida, Uttar Pradesh - 201301 India
Noida
Country India
Categories News , Research , Science
Tags agerelated macular degeneration market , agerelated macular degeneration market demand , agerelated macular degeneration market outlook , agerelated macular degeneration market trends
Last Updated November 21, 2019